Prevention of Mother-to-Child HIV Transmission Internationally

Data from the Joint United Nations Programme on HIV/AIDS (UNAIDS) indicate that in 2003, 34–46 million people were living with HIV infection, and three fourths of these cases were in sub-Saharan Africa. Approximately 2.1–2.9 million children were living with HIV/AIDS. HIV transmission in sub-Saharan Africa is predominately heterosexual, and by the end of 2002, women represented 58% of HIV cases. UNAIDS estimates that in many African countries <1% of pregnant women receive needed antiretroviral prophylaxis to prevent mother-to-child HIV transmission (PMTCT). This has a substantial impact on the death rate in children, with previous gains reversed for children <5 years of age in several countries.

Without intervention, the risk of mother-to-child HIV transmission is 30%–35%. With antenatal HIV testing, combination antiretroviral drugs, and safer infant feeding, the risk can be reduced to 1%–2%. Simplified short-course interventions can reduce PMTCT transmission to 15%–20%. Interventions for PMTCT should also be provided in the broader context of prevention, including primary prevention of HIV, preventing unintended pregnancies, and care and support to HIV-infected women and their families.

U.S. Government Response to Global Mother-to-Child HIV Transmission

In 2002, President George W. Bush introduced the International Mother and Child HIV Prevention Initiative. This initiative was coordinated across several U.S. government agencies including the Centers for Disease Control and Prevention (CDC) and U.S. Agency for International Development. The initiative focused on 14 countries in Africa and the Caribbean with high rates of HIV/AIDS. The goals of the initiative were to reduce mother-to-child transmission by up to 40%; support expanding national PMTCT programs; support linking PMTCT services with antiretroviral treatment and care for mothers, infants, and family members (PMTCT-plus); and reach up to 1 million women annually.

Core interventions include routinely recommending HIV counseling and testing at antenatal clinics, short-course antiretroviral prophylaxis for HIV-positive mother-infant pairs, counseling and support for safe infant feeding practices, and counseling for family planning. Additional interventions include prevention strategies for HIV-negative pregnant women and community mobilization to increase uptake and decrease stigma. By 2003, all 14 countries had started to provide services, and this initiative is now a major activity under the more comprehensive President’s Emergency Plan for AIDS Relief, which targets the same 14 countries plus Vietnam.

Implementing PMTCT Programs Internationally

Case Study in Kenya

Kenya has a population of 31.1 million, with 1.2 million births every year. Of the 2.2 million people living with HIV/AIDS in Kenya, 1.4 million are women. The most rapidly growing population becoming infected with HIV is women. HIV-positive women give birth to 118,000 children annually. An estimated 35,000–40,000 of those infants are HIV-positive. Ten percent of reported HIV/AIDS cases in Kenya are in children <5 years of age. PMTCT interventions include antiretroviral drug prophylaxis, optimal obstetric care, infant feeding counseling, and family planning. Replacement feeding (as opposed to breastfeeding) is only recommended in environments where it is acceptable, feasible, sustainable, and safe. Through the CDC Global AIDS Program in Kenya, 18,000 antenatal women have learned their HIV status, and 50% of those who are HIV-positive have received prophylactic antiretroviral drugs. Barriers to testing include a lack of spousal support, fear of partner violence, and fear of disclosure and the stigma that may accompany it.

Case Study in Botswana

Botswana’s 2003 surveillance data show that 37.4% of women attending antenatal clinics are HIV-positive. Botswana has had a national PMTCT program since 2001

---

First authors are session moderators. Remaining authors are listed in order topics were discussed. More session summaries are available at http://www.cdc.gov/ncidod/EID/vol10no11/icwid.htm.
Infectious Etiologies of Chronic Diseases: Focus on Women

Infections can directly or indirectly cause chronic conditions through progressive pathology (e.g., chronic infection, inflammation, immunity, malignant transformation), sudden permanent insults (e.g., West Nile virus poliomyelitis paralysis), or by predisposing people to non-infectious sequelae (e.g., neurologic consequences of preterm birth). Bacteria, parasites, prions, viruses, and fungi may be the single or one of several factors contributing to chronic disease; one organism can cause more than one syndrome, and diverse pathogens produce similar syndromes as pathways to disease converge (1). Certain potential outcomes disproportionately affect women (e.g., autoimmune diseases), and in some settings, detection, prevention, or treatment efforts (e.g., ocular trachoma, underdiagnosed genital infections) may marginalize women. Women’s activities can also increase exposures to chronic disease pathogens (e.g., schistosomiasis attributable to chores or agriculture), and gender can affect transmission (e.g., increased male-to-female transmission of human T-cell leukemia virus-1). Preventing maternal infections may further minimize chronic disease and neurodevelopmental disorders in offspring.

Are Women’s Autoimmune Diseases Really Autoimmune?

Systemic and organ-specific autoimmune diseases, such as rheumatoid arthritis and myocarditis, are the leading cause of death in women >65 years of age (2). They affect 14–22 million people (5%–8% of the population) in the United States (3) and millions more worldwide. In autoimmunity, the immune system may attack or damage self-tissues with autoantibodies and autoreactive T and B cells. However, the indolent nature of most autoimmune diseases makes determining infectious triggers difficult. Animal models help to understand such links. For example, transfer of disease by autoantibodies and immune cells from affected animals indicates the immune-mediated nature of these syndromes (4–6). Toll-like receptors and the innate immune system, critical components of the normal human response to infection, are essential to naturally and experimentally induced autoimmunity. Genetic and other factors affect susceptibility to both infection and autoimmune disease. For example, coxsackievirus B3 induces viral myocarditis in susceptible mice. Certain cytokines (interleukin [IL]-1 and tumor necrosis factor [TNF]-α), but not viral replication, correlate with cardiac inflammation and can overcome resistance to chronic myocarditis (7–9). These findings suggest that, while infection may trigger autoimmunity, immune processes drive disease progression. Estrogen amplifies the immune response to coxsackievirus B3 in susceptible mice, increasing TNF-α and IL-4 levels (unpub. data), which is perhaps consistent with women’s predisposition to autoimmune disease. Identifying triggers, including infection, and early markers of autoimmunity are important goals for preventing onset of or disrupting progression to autoimmune disease.

Infection Connection in Neurodevelopmental Disorders

Intrauterine infections are known causes of congenital defects worldwide. Infections during the time of fetal brain development might also contribute to neuropsychiatric disorders, including schizophrenia. Studies linking various gestational insults (including infections) and subtle premorbid behavioral alterations to adult schizophrenia imply a neurodevelopmental origin. However, the long